Exponent, Inc. (Nasdaq: EXPO) today reported financial results for
the first quarter of fiscal year 2025 ended April 4, 2025.
“Exponent’s first quarter results exceeded expectations,
reinforcing both the resilience of our diversified business model
and the value we deliver,” said Dr. Catherine Corrigan, President
and Chief Executive Officer. “Our failure analysis expertise drove
increased dispute-related activities in the chemicals,
transportation and utilities industries. Proactive engagements were
led by risk management and regulatory support activities. As
expected, we were impacted by easing in the consumer electronics
industry due to the timing of our clients’ product development life
cycles. Our work continues to play a pivotal role in helping
clients address their most complex and high-stakes challenges,
supporting data driven decisions across critical and large-scale
projects around the world.
“Exponent has demonstrated resilience through decades of
successfully navigating challenging economic cycles. This quality,
coupled with the accelerating pace of innovation and expectations
around safety, health, and the environment, positions Exponent well
to weather economic volatility,” Dr. Corrigan continued.
First Quarter Financial Results
Total revenues and revenues before reimbursements for the first
quarter of 2025 were approximately flat at $145.5 million and
$137.4 million, respectively, as compared to $144.9 million and
$137.2 million in the first quarter of 2024.
Net income decreased to $26.7 million, or $0.52 per diluted
share, in the first quarter of 2025, as compared to $30.1 million,
or $0.59 per diluted share, in the same period of 2024. During the
quarter, we realized a negative tax impact associated with
share-based awards of $0.5 million or $0.01 per share, as compared
to a positive benefit of $0.9 million, or $0.02 per share, in the
first quarter of 2024. Inclusive of the negative tax impact,
Exponent's consolidated tax rate was 29.4% in the first quarter, as
compared to 25.4% for the same period in 2024.
EBITDA1 decreased to $37.5 million, or 27.3% of net revenues, in
the first quarter of 2025, as compared to $40.1 million, or 29.2%
of net revenues in the first quarter of 2024.
In a separate press release today, Exponent announced its
quarterly cash dividend of $0.30 to be paid on June 20, 2025 and
reiterated its intent to continue to pay quarterly dividends.
During the first quarter of 2025, Exponent paid $16.4 million in
dividends and closed the period with $245.1 million in cash and
cash equivalents.
Business Overview
Exponent’s engineering and other scientific segment represented
84% of the Company’s revenues before reimbursements in the first
quarter of 2025. Revenues before reimbursements in this segment
were approximately flat in the first quarter, compared to the prior
year period. Activity during the quarter was driven by demand for
Exponent’s services across the transportation and utilities
industries.
Exponent’s environmental and health segment represented 16% of
the Company’s revenues before reimbursements in the first quarter.
Revenues before reimbursements in this segment increased 2% in the
first quarter, compared to the same period in the prior year.
Growth in this segment was primarily driven by increased
engagements in the chemicals industry.
Business Outlook
“As the broader market continues to navigate uncertainties,
Exponent remains uniquely positioned to weather heightened
turbulence enabled by our unparalleled and interconnected ecosystem
of talent and our diversified portfolio of services,” commented
Richard Schlenker, Executive Vice President and Chief Financial
Officer. “Based on current market demand, we continue to expect
growth in 2025 and are maintaining our full year guidance. However,
we continue to face headwinds in the second quarter as we close our
year over year headcount gap.”
For the second quarter of fiscal 2025 as compared to the same
period one year prior, Exponent anticipates:
- Revenues before reimbursements to be
down in the low-single digits; and,
- EBITDA1 to be 26.0% to 27.0% of
revenues before reimbursements.
As a reminder, we are returning to a 52-week fiscal year in
2025, which will pose a headwind for full-year comparisons since
fiscal 2024 benefitted from a 53rd week. For the full fiscal year
2025 as compared to fiscal year 2024, Exponent anticipates:
- Revenues before reimbursements to
grow in the low-single digits; and,
- EBITDA1 to be 26.25% to 27.0% of
revenues before reimbursements.
“Exponent thrives in the face of change, whether it’s driven by
innovation or disruption. As our clients navigate increasing
complexity, we remain focused on advancing our capabilities,
investing in top talent, and delivering trusted insights that help
our clients adapt, lead, and grow in dynamic environments,” Dr.
Corrigan concluded.
Today's Conference Call Information
Exponent will discuss its financial results in more detail on a
conference call today, Thursday, May 1, 2025, starting at 4:30 p.m.
Eastern Time / 1:30 p.m. Pacific Time. The audio of the conference
call is available by dialing (844) 481-2781 or (412) 317-0672. A
live webcast of the call will be available on the Investor
Relations section of the Company's website at
www.exponent.com/investors. For those unable to listen to the live
webcast, a replay of the call will also be available on the
Exponent website, or by dialing (877) 344-7529 or (412) 317-0088
and entering passcode 8332346#.
Use of non-GAAP Financial Measures
1
EBITDA is a non-GAAP financial measure defined by the Company as
net income before income taxes, interest income, depreciation, and
amortization. EBITDAS is a non-GAAP financial measure defined by
the Company as EBITDA before stock-based compensation. The Company
regards EBITDA and EBITDAS as useful measures of operating
performance and cash flow to complement operating income, net
income, and other GAAP financial performance measures.
Additionally, management believes that EBITDA and EBITDAS provide
meaningful comparisons of past, present, and future operating
results. Generally, a non-GAAP financial measure is a numerical
measure of a company's performance, financial position, or cash
flow that either excludes or includes amounts that are not normally
excluded or included in the most directly comparable measure
calculated and presented in accordance with GAAP. These measures,
however, should be considered in addition to, and not as a
substitute or superior to, operating income, cash flows, or other
measures of financial performance prepared in accordance with
GAAP.
Exponent has provided its outlook regarding EBITDA as a
percentage of revenues before reimbursements. The Company has not
reconciled this non-GAAP financial measure to the corresponding
GAAP financial measure because guidance for the various reconciling
items is not provided and the Company is unable to estimate with
reasonable certainty the effect of these items without unreasonable
effort. For example, the Company is unable to estimate with
reasonable certainty the impact of equity awards on Exponent’s
taxes without unreasonable effort. These items are uncertain,
depend on various factors, and may have a material effect on
Exponent’s results computed in accordance with GAAP. A
reconciliation between the historical GAAP and non-GAAP financial
measures presented in this release is provided in the financial
tables at the end of this release.
About Exponent
Exponent brings together 90+ technical disciplines and 950+
consultants to help our clients navigate the increasing complexity
of more than a dozen industries, connecting decades of pioneering
work in failure analysis to develop solutions for a safer,
healthier, more sustainable world.
Exponent's consultants deliver the highest value by leveraging
multidisciplinary expertise and resources from across Exponent's
offices in North America, Asia, and Europe. Exponent's consultants,
laboratories, databases, and computing resources work seamlessly
together around the globe, enabling us to produce the breakthrough
insights needed to help multinational companies, startups, law
firms, insurance companies, governments, and society respond to
incidents and push their products and processes forward.
Exponent may be reached at (888) 656-EXPO, info@exponent.com,
or www.exponent.com.
Forward Looking Statements
This news release contains, and incorporates by reference,
certain “forward-looking” statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995, and the rules
promulgated pursuant to the Securities Act of 1933, as amended, and
the Securities Exchange Act of 1934, as amended) that are based on
the beliefs of the Company’s management, as well as assumptions
made by and information currently available to the Company’s
management. When used in this document and in the documents
incorporated herein by reference, the words “intend,” “anticipate,”
“believe,” “estimate,” “expect” and similar expressions, as they
relate to the Company or its management, identify such
forward-looking statements. Such statements reflect the current
views of the Company or its management with respect to future
events and are subject to certain risks, uncertainties and
assumptions. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, the
Company’s actual results, performance, or achievements could differ
materially from those expressed in, or implied by, any such
forward-looking statements. Factors that could cause or contribute
to such material differences include the possibility that the
demand for our services may decline as a result of changes in
generally applicable and industry-specific economic conditions, the
timing of engagements for our services, the effects of competitive
services and pricing, the absence of backlog related to our
business, our ability to attract and retain key employees, the
effect of tort reform and government regulation on our business,
and liabilities resulting from claims made against us. Additional
risks and uncertainties are discussed in our Annual Report on Form
10-K under the heading “Risk Factors” and elsewhere in the report.
The inclusion of such forward-looking information should not be
regarded as a representation by the Company or any other person
that the future events, plans, or expectations contemplated by the
Company will be achieved. The Company undertakes no obligation to
release publicly any updates or revisions to any such
forward-looking statements.
Source: Exponent, Inc.
EXPONENT,
INC. |
|
CONDENSED
CONSOLIDATED STATEMENTS OF INCOME |
|
For the
Quarters Ended April 4, 2025 and March 29, 2024 |
|
(unaudited) |
|
(in thousands, except per share data) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarters Ended |
|
|
|
|
|
|
|
|
|
April
4, |
|
March
29, |
|
|
|
|
|
|
|
|
|
2025 |
|
2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
|
|
|
|
|
|
|
|
|
Revenues before reimbursements |
|
$ |
137,437 |
|
|
$ |
137,207 |
|
|
|
Reimbursements |
|
|
|
|
8,070 |
|
|
|
7,726 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
|
|
|
145,507 |
|
|
|
144,933 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
Compensation and related expenses |
|
|
75,903 |
|
|
|
90,327 |
|
|
|
Other operating expenses |
|
|
|
12,095 |
|
|
|
10,531 |
|
|
|
Reimbursable expenses |
|
|
|
8,070 |
|
|
|
7,726 |
|
|
|
General and administrative expenses |
|
|
5,007 |
|
|
|
5,636 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
101,075 |
|
|
|
114,220 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
|
44,432 |
|
|
|
30,713 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income |
|
|
|
|
|
|
|
|
|
|
Interest income, net |
|
|
|
2,714 |
|
|
|
2,626 |
|
|
|
Miscellaneous income, net |
|
|
|
(9,386 |
) |
|
|
7,084 |
|
|
|
|
|
|
|
|
|
|
(6,672 |
) |
|
|
9,710 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
|
37,760 |
|
|
|
40,423 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
|
|
|
11,110 |
|
|
|
10,281 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
$ |
26,650 |
|
|
$ |
30,142 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share: |
|
|
|
|
|
|
|
|
Basic |
|
|
|
|
$ |
0.52 |
|
|
$ |
0.59 |
|
|
|
Diluted |
|
|
|
|
$ |
0.52 |
|
|
$ |
0.59 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in per share computations: |
|
|
|
|
|
|
|
Basic |
|
|
|
|
|
51,283 |
|
|
|
51,006 |
|
|
|
Diluted |
|
|
|
|
|
51,650 |
|
|
|
51,419 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EXPONENT,
INC. |
|
CONDENSED
CONSOLIDATED BALANCE SHEETS |
|
April 4,
2025 and January 3, 2025 |
|
(unaudited) |
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
April
4, |
|
January 3, |
|
|
|
|
|
|
|
|
|
2025 |
|
2025 |
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
$ |
245,113 |
|
|
$ |
258,901 |
|
|
|
|
Accounts receivable, net |
|
|
|
166,788 |
|
|
|
161,407 |
|
|
|
|
Prepaid expenses and other assets |
|
|
20,895 |
|
|
|
26,573 |
|
|
|
|
|
Total current assets |
|
|
|
432,796 |
|
|
|
446,881 |
|
|
|
Property, equipment and leasehold improvements, net |
|
|
71,767 |
|
|
|
73,007 |
|
|
|
Operating lease right-of-use asset |
|
|
73,438 |
|
|
|
75,248 |
|
|
|
Goodwill |
|
|
|
|
|
8,607 |
|
|
|
8,607 |
|
|
|
Other assets |
|
|
|
|
|
176,631 |
|
|
|
173,527 |
|
|
|
|
|
Total assets |
|
|
|
$ |
763,239 |
|
|
$ |
777,270 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
$ |
36,783 |
|
|
$ |
22,136 |
|
|
|
|
Accrued payroll and employee benefits |
|
|
74,074 |
|
|
|
119,285 |
|
|
|
|
Deferred revenues |
|
|
|
|
13,782 |
|
|
|
16,369 |
|
|
|
|
Operating lease liability |
|
|
|
5,633 |
|
|
|
5,393 |
|
|
|
|
|
Total current liabilities |
|
|
130,272 |
|
|
|
163,183 |
|
|
|
Other liabilities |
|
|
|
|
|
117,071 |
|
|
|
116,935 |
|
|
|
Operating lease liability |
|
|
|
74,488 |
|
|
|
76,084 |
|
|
|
|
|
Total liabilities |
|
|
|
321,831 |
|
|
|
356,202 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
|
Common stock |
|
|
|
|
66 |
|
|
|
66 |
|
|
|
|
Additional paid-in capital |
|
|
|
361,776 |
|
|
|
345,689 |
|
|
|
|
Accumulated other comprehensive loss |
|
|
(2,845 |
) |
|
|
(3,791 |
) |
|
|
|
Retained earnings |
|
|
|
|
635,020 |
|
|
|
624,151 |
|
|
|
|
Treasury stock, at cost |
|
|
|
(552,609 |
) |
|
|
(545,047 |
) |
|
|
|
|
Total stockholders' equity |
|
|
441,408 |
|
|
|
421,068 |
|
|
|
|
|
Total liabilities & stockholders' equity |
|
$ |
763,239 |
|
|
$ |
777,270 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EXPONENT,
INC. |
|
EBITDA and
EBITDAS (1) |
|
For the
Quarters Ended April 4, 2025 and March 29, 2024 |
|
(unaudited) |
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarters Ended |
|
|
|
|
|
|
|
|
|
April
4, |
|
March
29, |
|
|
|
|
|
|
|
|
|
2025 |
|
2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income |
|
|
|
|
$ |
26,650 |
|
|
$ |
30,142 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Add back (subtract): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
|
|
11,110 |
|
|
|
10,281 |
|
|
|
|
Interest income, net |
|
|
|
(2,714 |
) |
|
|
(2,626 |
) |
|
|
|
Depreciation and amortization |
|
|
2,492 |
|
|
|
2,324 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA (1) |
|
|
|
|
37,538 |
|
|
|
40,121 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
|
8,179 |
|
|
|
7,340 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDAS (1) |
|
|
$ |
45,717 |
|
|
$ |
47,461 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) EBITDA is a
non-GAAP financial measure defined by the Company as net income
before income taxes, interest income, depreciation and
amortization. EBITDAS is a non-GAAP financial measure defined by
the Company as EBITDA before stock-based compensation. The Company
regards EBITDA and EBITDAS as useful measures of operating
performance and cash flow to complement operating income, net
income and other GAAP financial performance measures. Additionally,
management believes that EBITDA and EBITDAS provide meaningful
comparisons of past, present and future operating results.
Generally, a non-GAAP financial measure is a numerical measure of a
company's performance, financial position or cash flow that either
excludes or includes amounts that are not normally excluded or
included in the most directly comparable measure calculated and
presented in accordance with GAAP. These measures, however, should
be considered in addition to, and not as a substitute or superior
to, operating income, cash flows, or other measures of financial
performance prepared in accordance with GAAP. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Exponent (NASDAQ:EXPO)
Historical Stock Chart
From Jun 2025 to Jul 2025
Exponent (NASDAQ:EXPO)
Historical Stock Chart
From Jul 2024 to Jul 2025